Robert Alexander
Technik-/Wissenschafts-/F&E-Leiter bei Reunion Neuroscience, Inc.
Vermögen: - $ am 31.07.2023
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Joseph del Moral | M | 45 |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Gregory Mayes | M | 55 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 Jahre |
| Ellen Lubman | F | 48 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 Jahre |
| Barry Fishman | M | 67 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 Jahre |
| Dieter Weinand | M | 63 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 4 Jahre |
| Curtis Weber | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 Jahre |
| Ansbert Gadicke | M | 66 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Edward Smith | M | 53 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 Jahre |
| Nathan Bryson | M | 61 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 2 Jahre |
| Kristen Laguerre | F | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Fred Grossman | M | 62 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 1 Jahre |
| Hannan Fleiman | M | 44 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 5 Jahre |
| Jonathan See | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Helen Boudreau | F | 58 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 3 Jahre |
| Michael Verbora | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Syed Mujeeb Jafferi | M | 41 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Amardeep Manhas | M | 41 |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | - |
| Aviva Asnis-Alibozek | M | - |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada. | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Kanada | 18 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Robert Alexander
- Persönliches Netzwerk